Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers
Psychopharmacology Bulletin · 2025
DOI: 10.64719/pb.4511 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Psychopharmacology Bulletin, 2025. Verfasst von VYu Skryabin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Ru…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Hallucinations, Precision Medicine, Haloperidol. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Alcoholic hallucinosis (AH) is one of the severe complications of chronic alcoholism, characterized by psychotic symptoms such as auditory hallucinations and delusions. Haloperidol is widely used to treat AH; however, its therapy is often complicated by side effects. A personalized approach using pharmacogenetic testing (particularly the CYP2D6 polymorphism) allows individualization of haloperidol dosage, improving both safety and efficacy of therapy. Materials and Methods The study included 100 men diagnosed with “psychotic disorder induced by alcohol use.” Patients were randomized into two groups: the main group (45 patients) received haloperidol based on the results of pharmacogenetic testing, while the control group (55 patients) received standard dosing. Genotyping was conducted for the CYP2D6 1846G > A polymorphism. The effectiveness was assessed using the PANSS, UKU, and SAS scales.
Results
Genotyping showed an even distribution of CYP2D6 polymorphisms in both groups. The main group demonstrated a significant reduction in side effects and improvement in psychotic symptoms compared to the control group. Differences on the UKU, SAS, and PANSS scales reached statistical significance on days 3–5 of treatment.
Conclusion
Using pharmacogenetic testing to adjust haloperidol dosage improves therapy tolerability and accelerates the resolution of psychotic symptoms in patients with alcoholic hallucinosis, confirming the feasibility of a personalized approach in psychopharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skryabin, PhD, MD, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia; Associate professor of addiction psychiatry department, Russian…
- Petukhov, PhD, MD, clinical laboratory diagnostician of the analytical toxicology lab of the Reference center for psychoactive substances use monitoring, Moscow Research and Practical Centre on Addictions of the Moscow…
- Pozdniakov, researcher of the laboratory of genetics and fundamental studies, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Ivanchenko, laboratory assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Zaytsev, laboratory assistant, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
- Miroshkin, head of clinical department, Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, Moscow, Russia.
Zitieren
APA
Skryabin, V., Petukhov, A. E., Pozdniakov, S. A., Ivanchenko, V. A., Zaytsev, I. A., Miroshkin, S. S., Sokolova, S. I., Bure, I. V., Smirnov, V. V., & Sychev, D. A. (2025). Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4511
Vancouver
Skryabin V, Petukhov AE, Pozdniakov SA, Ivanchenko VA, Zaytsev IA, Miroshkin SS, et al. Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers. Psychopharmacology Bulletin. 2025. doi:10.64719/pb.4511
BibTeX
@article{Skryabin2025,
author = {Skryabin, VYu and Petukhov, A E and Pozdniakov, S A and Ivanchenko, V A and Zaytsev, I A and Miroshkin, S S and Sokolova, S I and Bure, I V and Smirnov, V V and Sychev, D A},
title = {Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers},
journal = {Psychopharmacology Bulletin},
year = {2025},
doi = {10.64719/pb.4511}
}
EUVIMED